Theralase Technologies Inc. Welcomes Renowned Veterinarian to Medical & Scientific Advisory Board

TORONTO, ONTARIO--(Marketwire - August 09, 2010) - Theralase Technologies Inc. (TSX VENTURE: TLT) announces a new addition to its Medical and Scientific Advisory Board (MSAB).

Dr. Terry Ruch DVM, renowned veterinarian to the equine market, has agreed to join Theralase’s MSAB in the capacity of equine medical consultant. Dr. Ruch is a graduate of the University of Guelph (1974) and has devoted his practice to equine medicine - focusing on the diagnostic and orthopaedic examination of equine athletes. Dr. Ruch has been deeply involved with equine sports medicine for the past 36 years and is highly regarded in his field.

Dr. Ruch joins the following distinguished MSAB board members:

 Dr. James Andrews American Sports Medicine Institute Chair and Medical Director, Founder and Orthopaedic Surgeon - Andrews Sports Medicine and Orthopaedic Center, Birmingham, Alabama and Andrews Institute, Gulf Breeze, Florida, Senior Orthopaedic and Medical Consultant to collegiate & professional sports teams. Dr. Lyle Cain Fellowship Director and Senior staff member - American Sports Medicine Institute, Orthopaedic Surgeon - Andrews Sports Medicine and Orthopaedic Center, Birmingham, Alabama, Orthopaedic and Medical Consultant to collegiate sports teams with numerous orthopaedic and medical affiliations. Dr. Jeffrey Dugas Fellowship Director and Senior staff member - American Sports Medicine Institute, Orthopaedic Surgeon - Andrews Sports Medicine and Orthopaedic Center, Birmingham, Alabama, Orthopaedic and Medical Consultant to collegiate sports teams with numerous orthopaedic and medical affiliations. Kevin Wilk, DPT Affiliate Member of the American Orthopaedic Society for Sports Medicine, President - Sports Physical Therapy Section of the American Physical Therapy Association. Lanier Johnson Executive Director of the American Sports Medicine Institute, Developer of the Sports Medicine and Fitness Program and Traveling Van facility for the PGA tour. 

Roger Dumoulin-White, President and CEO of Theralase Technologies Inc. stated, “Dr. Ruch brings to the MSAB a wealth of experience, expertise and knowledge in equine medicine that will complement our already distinguished board who are medical experts in human orthopaedic and rehabilitative medicine. We are excited about what Dr. Ruch will contribute to Theralase, particularly as it relates to research and new clinical applications of the Theralase technology in the equine market. Dr. Ruch’s addition to the MSAB allows Theralase the opportunity to expand the use of our Theralase laser technology into the equine marketplace, creating a new source of revenue for the company.”

Dr. Terry Ruch stated, “I am delighted to join the Theralase Medical and Scientific Advisory Board and welcome the opportunity to add my years of equine athlete knowledge to a revolutionary product, such as the Theralase TLC-1000 Therapeutic Medical Laser. The Theralase is able to increase efficacy, provide superior clinical outcomes and allow for faster return to competition for many equine athletes. The Theralase works extremely well at reducing pain and inflammation, working on numerous soft tissue injuries, such as: muscles, tendons and ligaments.”

Visit the corporate or regulatory website at www.theralase.com or www.sedar.com for more information.

Theralase Technologies Inc. designs, develops and manufactures patented, super-pulsed laser technology utilized in bio-stimulation and bio-destruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular skeletal conditions and wound care. When combined with patented light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria and viruses.

This press release contains forward-looking statements which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.